insitro Acquires Haystack Sciences

Coframe Acquires HaystacksAI

March 4, 2026

AI & Machine Learning

Coframe announced it has acquired HaystacksAI, an AI-powered growth and sales intelligence startup, to strengthen its autonomous experimentation platform and expand go-to-market capabilities. HaystacksAI founder and CEO Bo Mohazzabi joined Coframe as Vice President of Go-To-Market to lead sales, growth, and customer strategy and contribute to the product roadmap.

HaystackID Acquires eDiscovery AI

February 26, 2026

IT Services

HaystackID announced it has acquired AI legal technology company eDiscovery AI to accelerate client-driven GenAI workflows for legal, compliance, regulatory, and cybersecurity matters. The acquisition builds on an existing collaboration, integrates eDiscovery AI technology into HaystackID’s core AI offerings, and the companies will operate eDiscovery AI as a separate business entity to support client flexibility; financial terms were not disclosed.

insitro to Acquire CombinAbleAI

January 12, 2026

AI & Machine Learning

insitro announced it will acquire CombinAbleAI and launch its TherML (Therapeutic Machine Learning) platform to unify AI-driven therapeutic design across drug modalities. The acquisition is expected to close in late January 2026, with CombinAbleAI’s team continuing to operate in Israel as a new insitro R&D center focused on large-molecule design.

Quest Diagnostics Acquires Haystack Oncology

April 27, 2023

Healthcare Services

Quest Diagnostics has agreed to acquire Haystack Oncology in an all-cash transaction valued at $300 million at closing plus up to $150 million in potential milestones. The acquisition adds Haystack's sensitive ctDNA-based minimal residual disease (MRD) liquid biopsy technology to Quest's oncology, genomics and pathology capabilities to expand clinical lab services for MRD testing beginning in 2024.

Inscripta Acquires Infinome Biosciences and Sestina Bio

January 18, 2023

Biotechnology

Inscripta, a genome engineering company based in Pleasanton, California, has acquired synthetic biology firms Infinome Biosciences and Sestina Bio to accelerate its capabilities in sustainable biomanufacturing. The acquisitions integrate Infinome's GenoScaler strain-engineering platform and Sestina's data-driven scale-up strain design to advance Inscripta's commercialization of bio-manufactured products for industrial and consumer markets.

X-Chem Acquires IntelliSyn and AviSyn to Expand Drug Discovery Services

January 26, 2021

Biotechnology

X-Chem, a portfolio company of GHO Capital, has acquired Montreal-based IntelliSyn and its US-based sister company AviSyn to extend its drug discovery offering into medicinal chemistry, custom synthesis and scale-up process chemistry. The deal integrates downstream hit validation and lead optimisation capabilities into X-Chem’s DNA-Encoded Library (DEL) platform, enabling a streamlined screen-to-lead service for pharma and biotech clients; financial terms were not disclosed.